Fluvastatin: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Fluvastatin. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Headache | 8.9% |
| Dyspepsia | 7.9% |
| Influenza-like symptoms | 7.1% |
| Accidental trauma | 5.1% |
| Myalgia | 5% |
| Diarrhea | 4.9% |
| Abdominal pain | 4.9% |
| Sinusitis | 3.5% |
| Arthropathy | 3.2% |
| Nausea | 3.2% |
| Insomnia | 2.7% |
| Urinary tract infection | 2.7% |
| Fatigue | 2.7% |
| Bronchitis | 2.6% |
| Flatulence | 2.6% |
| Allergy | 2.3% |
| Arthritis | 2.1% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Hypercholesterolemia (heterozygous familial and nonfamilial) and Mixed Dyslipidemia Lescol® (fluvastatin sodium) and Lescol® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate. Heterozygous Familial Hypercholesterolemia in Pediatric Patients Lescol and Lescol XL are indicated as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia whose response to dietary restriction has not been adequate and the following findings are present: LDL-C remains > 190 mg/dL or LDL-C remains > 160 mg/dL and: there is a positive family history of premature…
Medical disclaimer: Always consult a qualified healthcare professional about any medication.